➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
McKesson
Medtronic
Harvard Business School
Merck

Last Updated: October 19, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 209203

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 209203 describes DUZALLO, which is a drug marketed by Ironwood Pharms Inc and is included in one NDA. There are nine patents protecting this drug. Additional details are available on the DUZALLO profile page.

The generic ingredient in DUZALLO is allopurinol; lesinurad. There are twenty-two drug master file entries for this compound. Additional details are available on the allopurinol; lesinurad profile page.
Summary for 209203
Tradename:DUZALLO
Applicant:Ironwood Pharms Inc
Ingredient:allopurinol; lesinurad
Patents:9
Generic Entry Opportunity Date for 209203
Generic Entry Date for 209203*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength200MG;200MG
Approval Date:Aug 18, 2017TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Nov 26, 2028Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
Patent:  Start TrialPatent Expiration:Aug 25, 2025Product Flag?Substance Flag?YDelist Request?
Patent:  Start TrialPatent Expiration:Aug 17, 2029Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Mallinckrodt
Dow
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.